PressAugust 8, 2023 Filament Health Announces FDA Approval of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate PEX010
PressAugust 8, 2023 Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
PressAugust 4, 2023 Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
PressAugust 4, 2023 MindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120
PressAugust 4, 2023 FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink
PressAugust 3, 2023 COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights
PressAugust 3, 2023 Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
PressAugust 3, 2023 Reunion Neuroscience Inc. and MPM BioImpact Announce Completion of Plan of Arrangement
PressAugust 3, 2023 Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
PressAugust 3, 2023 Optimi Completes Proprietary Natural Psilocybin Extraction Process and Files U.S. Provisional Patent
BlogAugust 2, 2023 Fraser Johnston Inspires Healthy and Cooperative Communities – Podcast Episode #33
PressJuly 31, 2023 Psilocybin Potency, The Missing Link For Magic Mushroom Safety: Oakland’s Psychedelic Mushroom Church Announces Groundbreaking Information for Safe Use of Psilocybin Mushrooms
PressJuly 31, 2023 COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
PressJuly 28, 2023 Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
PressJuly 28, 2023 Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents
